Top 10 Low Price Companies To Own For 2014

Nationwide gas prices are falling in the wake of weak demand.

NEW YORK (CNNMoney) Gas prices in Missouri dipped below $3 per gallon on Friday, the first time in more than eight months.

The average price of unleaded gasoline dropped to $2.991 per gallon in Missouri, cementing its status as the state with the lowest gas prices in the country, according to motorist club AAA.

Missouri's proximity to refineries in the Midwest are a big reason for its low prices, according to oil trader Dan Dicker, author of "Oil's Endless Bid."

"It's about supply and transport costs," he said. "Basically, the states closest to the refiners will get a greater benefit than those further away.

The Midwestern refineries get their oil from the Bakken shale formation in North Dakota and Montana, and the Eagle Ford formation in Texas, which have been experiencing a glut in supply, said Dicker.

Hot Beverage Companies To Own For 2015: Navios Maritime Partners LP (NMM)

Navios Maritime Partners L.P. (Navios Partners) is an international owner and operator of dry cargo vessels formed by Navios Holdings. Navios GP L.L.C. (the General Partner), a wholly owned subsidiary of Navios Maritime Holdings Inc. (Navios Holdings) acts as the general partner of Navios Partners and received a 2% general partner interest in Navios Partners. Navios Partners is engaged in the seaborne transportation services of a range of drybulk commodities, including iron ore, coal, grain and fertilizer, chartering its vessels under medium to long-term charters. On May 19, 2011, Navios Partners acquired from Navios Holdings the Navios Orbiter, a 76,602 deadweight Panamax vessel. On May 19, 2011, Navios Partners acquired from Navios Holdings the Navios Luz. In June 2012, the Company purchased the Navios Buena Ventura, a 2010 South-Korean-built Capesize vessel of 179,259 dwt from Navios Maritime Holdings Inc.

The Company is an international owner and operator of drybulk carriers formed by Navios Maritime Holdings Inc., a vertically integrated seaborne shipping company. Its vessels are chartered-out under medium to long-term time charters with an average remaining term of approximately four years to a group of counterparties, consisting of Cosco Bulk Carrier Co. Ltd., Mitsui O.S.K. Lines Ltd., Samsun Logix, STX Panocean, Sanko Steamship Co. Ltd., Daiichi Chuo Kisen Kaisha, Augustea Imprese Maritime, Rio Tinto, Constellation Energy Group and Mansel.

As of December 31, 2011, the Company�� fleet consisted of 11 Panamax vessels, six Capesize vessels and one Ultra-Handymax vessel. Its fleet of dry cargo vessels has an average age of approximately 5.6 years. Panamax vessels are flexible vessels capable of carrying a range of drybulk commodities, including iron ore, coal, grain and fertilizer. All of its vessels operate under medium to long-term time charters of three or more years at inception with counterparties. It also operates vessels in the spot market until the vessels have! been fixed under appropriate medium to long-term charters.

The Company competes with China Ocean Shipping, China Shipping Group, Mitsui O.S.K. Lines, Kawasaki Kisen, Nippon Yusen Kaisha, Cargill, Pacific Basin Shipping, Bocimar, Zodiac Maritime, Louis Dreyfus/Cetragpa, Cobelfret and Torvald Klaveness.

Advisors' Opinion:

• [By Eric Volkman]

  As far as unitholder payouts are concerned, the seas for Navios Maritime Partners (NYSE: NMM  ) are calm and smooth. The company has declared its latest quarterly distribution, which is to be $0.4425 per unit paid on Aug. 13 to holders of record as of Aug. 8. That amount matches each of Navios' previous four disbursements, the most recent of which was paid in mid-May. Previous to that, the company handed out a quarter-cent less, at $0.44 per share.

• [By Igor Greenwald]

  Our Aggressive Portfolio already includes one beneficiary of these trends��avios Maritime Partners (NMM), a partnership with 25 dry bulk carriers, and now, five newly-acquired container ships.

Top 10 Low Price Companies To Own For 2014: Banro Corp (BAA)

Banro Corporation (Banro) is a Canada-based gold exploration company. The Company holds, through four wholly owned subsidiaries, a 100% interest in four gold properties, which are known as Twangiza, Namoya, Lugushwa and Kamituga. These properties are covered by a total of 13 exploitation permits and are found along the 210 kilometer-long Twangiza-Namoya gold belt in the South Kivu and Maniema Provinces of eastern Democratic Republic of the Congo (DRC). The Company also holds 14 exploration permits covering an aggregate of 2,638 square kilometers. Its 10 of the permits are located in the vicinity of the Company's Twangiza property and four are located in the vicinity of the Company's Namoya property. During the year ended December 31, 2011, the Company was engaged in the construction of the Company�� Twangiza Phase I oxide mine, and continued its exploration activities at its Twangiza, Namoya and Lugushwa properties. Advisors' Opinion:

• [By Anthony Mirhaydari]

  I’ve added shares of BVN to my Edge Letter Sample Portfolio.

  Breakout Gold Stocks to Buy: Banro (BAA)

  
  Click to Enlarge Banro (BAA) is a gold mining outfit with operations in the Democratic Republic of the Congo. The company recently announced a 15% increase in gold production in the fourth quarter thanks to expansion and efficiency gains at its Twangiza facility.

• [By Bryan Murphy]

  Looking for a couple of long (bullish) trading ideas on a day when the market is dragging pretty much everything lower? There are two names that fit the bill...CombiMatrix Corp. (NASDAQ:CBMX) and Banro Corporation (NYSEMKT:BAA). CBMX is an "almost" small cap stock that deserves a place on your watchlist while we wait for it to do one more thing. Meanwhile, BAA is something worth going ahead and taking a swing on now, not despite the market's tumble, but because of it.

Top 10 Low Price Companies To Own For 2014: iShares Global Tech ETF (IXN)

iShares S&P Global Technology Sector Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the Standard & Poor�� Global Information Technology Sector Index (the Index). The Index is a subset of the Standard & Poor�� Global 1200 Index, and measures the performance of companies that Standard & Poor�� deems to be part of the information technology sector. Component companies include those involved in the development and production of technology products, including computer hardware and software, telecommunications equipment, microcomputer components, integrated computer circuits and office equipment utilizing technology.

The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Fund�� investment advisor is Barclays Global Fund Advisors.

Advisors' Opinion:

• [By Russ Koesterich]

  The list above is based on my team's analysis of whether sector valuations appropriately price in each sector's expected earnings growth, profitability and risk. Based on these factors, I have a preference for the energy and informational technology sectors, accessible through the iShares S&P Global Energy Sector Fund (IXC) and the iShares S&P Global Technology Sector Fund (IXN). And as I write in my new Investment Directions commentary piece, if it turns out that we do see more investors rotating out of defensives and into more attractively priced cyclicals, these two sectors are poised to especially benefit.

Top 10 Low Price Companies To Own For 2014: Nikon Corp (NINOF)

NIKON CORPORATION is mainly engaged in the manufacture and sale of image and video equipment. The Company operates in four business segments. The Precision Equipment segment offers semiconductor exposure apparatus and liquid crystal (LC) exposure apparatus. The Image segment provides digital single-lens reflex (SLR) cameras, compact digital cameras and interchangeable lens. The Instruments segment offers microscopes, measuring machines and semiconductor inspection equipment. The Others segment provides LC photomask substrates and optical components. As of March 31, 2013, the Company has 87 subsidiaries and 10 associated companies. Advisors' Opinion:

• [By MARKETWATCH]

  LOS ANGELES (MarketWatch) -- With the yen holding on to its gains and investors cautious as earnings season kicks off, Japanese stocks slid lower Friday after closing the previous day with some late-session gains. The Nikkei Stock Average (JP:NIK) fell 0.9% to 14,358.28, with the Topix down 0.8%, as the dollar bought 97.36 yen, little changed from 24 hours earlier. The relatively strong yen weighed on some names with high global exposure, as Sharp Corp. (JP:6753) (SHCAF) lost 1%, Pioneer Corp. (JP:6773) (PNCOF) dropped 1.6%, and Bridgestone Corp. (JP:5108) (BRDCF) fell 1.2%. An outlook cut from Canon Inc. (JP:7751) (CAJ) helped send its shares down 1%, while rival Nikon Corp. (JP:7731) (NINOF) lost 1.8%, though Olympus Corp. (JP:7733) (OCPNF) gained 1%. Telecoms were weak, with Softbank Corp. (JP:9984) (SFTBF) falling 2.5%, KDDI Corp. (JP:9433) (KDDIF) down 1.7%, and NTT DoCoMo Inc. (JP:9437) (NTDMF)

• [By MARKETWATCH]

  LOS ANGELES (MarketWatch) -- Japanese stocks opened lower Thursday, as gains for the yen and losses for Wall Street conspired to drive the Nikkei Stock Average (JP:NIK) down 1.2% to 15,333.35, extending Wednesday's 0.6% loss. The Topix fell 0.7%, with the U.S. dollar (USDJPY) slipping to 102.46 yen, down from around 楼102.80 at the start of the previous session, but off its lows in late Wednesday trade. Electronics firms and other techs helped lead the loss, with Sony Corp. (JP:6758) (SNE) falling 1.4%, Nikon Corp. (JP:7731) (NINOF) off 2.4%, and Alps Electric Co. (JP:6770) 1.8% lower. The Nikkei Asian Review reported Thursday that Japan looked set to post its first trade deficit for electronics goods this year. Shares of Yahoo Japan Corp. (JP:4689) (YAHOF) lost 1.4%, even as Bloomberg reported the firm was offering its stake in market-research firm Macromill Inc. (JP:3730) to U.S. private-equity firm Bain Capital at a premium to its most recent close. Shares of Macromill were untraded. Among gainers, Nippon Telegraph & Telephone Corp. (JP:9432) (NTT) rose 2.1%, following a 1.1% gain for its U.S.-listed shares.

Top 10 Low Price Companies To Own For 2014: Derma Sciences Inc.(DSCI)

Derma Sciences, Inc. operates as a medical technology company. The company provides advanced wound care products, including Medihoney dressings that are used for the management of non-chronic and hard-to-heal wounds, such as chronic ulcers, burns, and post-operative wounds; Bioguard dressings that are used for prophylactic use in the prevention of hospital or community acquired infections through wound sites; Algicell Ag, antimicrobial dressings; Xtrasorb dressings that convert fluid within the dressings to a gel and lock the exudates into the dressings; TCC-EZ, a dressing system for the management of diabetic foot ulcers; and occlusive dressings, such as hydrocolloids, foams, hydrogels, alginates, additional silver antimicrobial dressings, cleansers, and Dermagran products. It also offers traditional wound care products, such as of gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages, and other compression devices, as well as a dhesive bandages and related first aid products. In addition, the company provides pharmaceutical wound care products, including DSC127, an angiotensin analog for use in wound healing and scar reduction. It markets wound closure strips, nasal tube and catheter fasteners, barrier creams and ointments, antibacterial cleansing foams and sprays, shampoos and body washes, hand sanitizers, bath additives, body oils, and moisturizers to doctors, clinics, nursing homes, hospitals, home healthcare agencies, and other institutions. The company sells its products to health care providers, such as wound care centers, extended care facilities, acute care facilities, home health care agencies, and physicians? offices through direct sales representatives in the United States, Canada, and the United Kingdom; retail channels; manufacturers? representatives and independent distributors in international markets. Derma Sciences, Inc. was founded in 1984 and is headquartered in Princeton, New Jersey.

Advisors' Opinion:

• [By Alexander Maxwell]

  Grafix has raised the bar on chronic diabetic foot ulcer treatment. Another company developing treatments for CDFU is Derma Sciences� (NASDAQ: DSCI  ) . Derma is developing a treatment called DSC 127, which is currently in phase 3 trials with results expected in 2015.

• [By John Udovich]

  Small cap stocks Derma Sciences Inc (NASDAQ: DSCI), Oculus Innovative Sciences, Inc (NASDAQ: OCLS)�and Arch Therapeutics Inc (OTCBB: ARTH) specialize or have a focus on wound care���a medical problem that has plagued mankind since the dawn of time. After all and think back to our Civil War when disease along with infections resulting from improper wound care probably killed more soldiers than actual battles. Even today, infection after surgery or after receiving a wound or injury of any kind is still a constant threat. And then there is the scaring that can result from any sort of invasive surgery or injury. With those thoughts in mind, here are three small cap wound care stocks trying address these problems:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Derma Sciences (Nasdaq: DSCI  ) , whose recent revenue and earnings are plotted below.

Top 10 Low Price Companies To Own For 2014: Titan Pharmaceuticals Inc (TTNP.OB)

Titan Pharmaceuticals, Inc., incorporated in February 1992, is a biopharmaceutical company developing therapeutics primarily for the treatment of central nervous system (CNS) disorders. The Company is focused primarily on clinical development of products that include Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders, and Spheramine for the treatment of advanced Parkinson�� disease. Titan Pharmaceuticals is directly developing its product candidates and also utilizing corporate partnerships, including a collaboration with Bayer Schering Pharma AG, Germany (Bayer Schering) for the development of Spheramine to treat Parkinson�� disease, and Vanda Pharmaceuticals, Inc. (Vanda) for the development of iloperidone for the treatment of schizophrenia and related psychotic disorders.

Probuphine

Probuphine is the first product to utilize the Company�� ProNeura long-ter m drug delivery technology. Probuphine is designed to provide continuous, long-term therapeutic levels of the drug buprenorphine, an approved agent for the treatment of opioid addiction. In December 2007, the Company completed enrollment in a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study of Probuphine in the treatment of opioid addiction. This 150 patient study, which is being conducted in the United States, will evaluate the safety and effectiveness of treatment with Probuphine versus placebo in reducing opioid addiction over 24 weeks of treatment. This study is part of a registration directed program intended to obtain marketing approval of Probuphine for the treatment of opioid addiction in Europe and the United States.

Iloperidone

Iloperidone was evaluated in a Phase III program comprising over 3,500 patients at more than 200 sites in 24 countries, administered and funded by Novartis Pharma AG (Novartis). In three completed efficacy studies conducted by Novartis, ! i! loperidone statistically reduced the symptoms of schizophrenia compared to placebo. Iloperidone has also been investigated in three 12-month safety studies, which confirm safety and tolerability. A dose dependent increase in the Q-T Corrected (QTc) interval was observed and investigated further in a clinical study, and no clinically significant adverse events were observed. In September 2007, Vanda submitted a new drug application (NDA) with the United States Food and Drug Administration (FDA) for iloperidone. The NDA for iloperidone was officially accepted for review by the FDA in November 2007.

Spheramine

Spheramine is a cell-based therapeutic that utilizes the Company�� cell-coated microcarrier (CCM) technology, which enables the development of cell-based therapies for minimally invasive, site-specific delivery to the central nervous system of therapeutic factors precisely where they are needed. Spheramine consists of microcarriers coated wit h human retinal pigment epithelial cells that are intended to enhance brain levels of dopamine, a neurotransmitter deficient in certain brain regions in Parkinson�� disease, leading to movement disorders. Preclinical studies have demonstrated the preliminary efficacy and safety of Spheramine, including blinded studies in a primate model of Parkinson�� disease. In June 2007, enrollment was completed in a current multi-center, randomized, double-blind, placebo-controlled clinical trial of Spheramine in Parkinson�� disease. This Phase IIb clinical study enrolled 71 patients with advanced Parkinson�� disease (Hoehn and Yahr Stages III and IV) to further evaluate the efficacy, safety, and tolerability of Spheramine.

Bayer Schering, the Company�� corporate partner for worldwide development and commercialization of Spheramine, is funding the clinical development program for Spheramine. Under an agreement, Bayer Schering has received exclusive, worldwide deve lopment, manufacturing and commercialization rights, an! d, in! ad! dition! to the clinical and manufacturing development funding and milestone payments, Bayer Schering will pay Titan Pharmaceuticals a royalty on future product sales.

Advisors' Opinion:

• [By C.R. Jackson]

  Fanapt was discovered by Hoechst Marion Roussel in 1995 as a novel atypical antipsychotic agent. Hoechst was a German life-sciences company that became Aventis Deutschland after its merger with France's Rhône-Poulenc in 1999. When the company joined with Sanofi-Synthélabo in 2004, it became a subsidiary of the Sanofi-Aventis (SNY) the French pharmaceutical conglomerate. In 1997, Hoechst sold the research rights to Titan Pharmaceuticals (TTNP.OB). Then Titan quickly sold the worldwide rights to Novartis in 1998. Novartis then sold the Phase 3 development rights for loperidone to Vanda in 2004. Vanda originally attempted to get FDA approval for Fanapt in 2008, but the FDA refused to approve iloperidone. The agency required an additional clinical trial.

Top 10 Low Price Companies To Own For 2014: Euler Hermes SA (ELE)

Euler Hermes SA is a France-based credit insurance company. It offers a range of services, including loan assurance, risk assessment, trade debt collection, compensation of losses due to buyer insolvency, bonding and guarantees for companies, reinsurance of loans to individuals and fidelity insurance covering companies against financial loss caused by fraudulent acts. It operates a number of subsidiaries, including Euler Hermes SFAC, Euler Hermes ACI Holding Inc., Euler Hermes Reinsurance AG, among others. On January 1, 2012, the Company completed the simplification of its legal structure in Europe by grouping 13 of its former subsidiaries into one insurance company, Euler Hermes Europe, located in Brussels. Advisors' Opinion:

• [By Sarah Jones]

  Iberdrola SA (IBE), Spain�� biggest power company, fell 3.4 percent to 3.87 euros. Endesa SA (ELE) slumped 4.6 percent to 16 euros, while Acciona SA (ANA), which owns more than 4 gigawatts of wind farms in the country, tumbled 8.5 percent to 37.95 euros. Red Electrica Corp. slid 7.5 percent to 38.34 euros.